Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 6/20 | 0.58 |
| ▸ | PIM1 | P11309 | 5/20 | 0.58 |
| ▸ | GSK3B | P49841 | 5/20 | 0.58 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.58 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.58 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.58 |
| ▸ | CCNK | O75909 | 1/20 | 0.50 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.44 |
| ▸ | CLK1 | P49759 | 1/20 | 0.44 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.43 |
| ▸ | AURKA | O14965 | 2/20 | 0.43 |
| ▸ | PRKCI | P41743 | 2/20 | 0.43 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.41 |
| ▸ | IKBKB | O14920 | 2/20 | 0.40 |
| ▸ | CHUK | O15111 | 2/20 | 0.40 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1431439 | 0.88 | PIK3CD (0.69) | PIK3CDPIM1GSK3BPIK3CGPIK3CB | |
| SCHEMBL456830 | 0.79 | PIK3CD (0.51) | PIK3CDPIM1GSK3BPIK3CGPIK3CB | |
| SCHEMBL457541 | 0.79 | PIK3CD (0.66) | PIK3CDPIM1GSK3BPIK3CGPIK3CB | |
| SCHEMBL13570110 | 0.79 | PIK3CD (0.62) | PIK3CDPIM1GSK3BPIK3CGPIK3CB | |
| SCHEMBL459229 | 0.78 | PIK3CD (0.59) | PIK3CDPIM1GSK3BPIK3CGPIK3CB | |
| SCHEMBL2213951 | 0.78 | PIK3CD (0.54) | PIK3CDPIM1GSK3BPIK3CGPIK3CB | |
| SCHEMBL456454 | 0.77 | PIK3CD (0.67) | PIK3CDPIM1GSK3BPIK3CGPIK3CB | |
| SCHEMBL2212949 | 0.76 | PIK3CD (0.51) | PIK3CDPIM1GSK3BPIK3CGPIK3CB | |
| SCHEMBL2212561 | 0.75 | PIK3CD (0.76) | PIK3CDPIM1GSK3BPIK3CGPIK3CB | |
| SCHEMBL1782113 | 0.75 | PIK3CD (0.55) | PIK3CDPIM1GSK3BPIK3CGPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238571-A1 | INDAZOLE DERIVATIVES AS PI 3-KINASE | GLAXO GROUP LIMITED (GB) | 2012-09-20 | — | — | US | claimed |
| US-20120238559-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-09-20 | — | — | US | claimed |
| US-9326987-B2 | Indazole derivatives for use in the treatment of influenza virus infection | GLAXO GROUP LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| US-9326987-B2 | Indazole derivatives for use in the treatment of influenza virus infection | GLAXO GROUP LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| US-9326987-B2 | Indazole derivatives for use in the treatment of influenza virus infection | GLAXO GROUP LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| US-20130165433-A1 | Novel Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| US-20130165433-A1 | Novel Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| US-20130165433-A1 | Novel Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| US-20120238559-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-09-20 | — | — | US | disclosed |
| US-20120238559-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-09-20 | — | — | US | disclosed |
| US-20120238559-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-09-20 | — | — | US | disclosed |
| WO-2012032065-A1 | INDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF INFLUENZA VIRUS INFECTION | GLAXO GROUP LIMITED (GB) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165433-A1 | Novel Use | HAVCR2, MAVS, ENTPD5 | PIK3CD 2938/4885PIM1 1258/4885GSK3B 389/4885 |
| US-20120238559-A1 | NOVEL COMPOUNDS | PIK3CA, PIK3CD, PIK3C2B | PIK3CD 2/4885PIM1 100/4885GSK3B 35/4885 |
| US-20120238571-A1 | INDAZOLE DERIVATIVES AS PI 3-KINASE | PI4KA, PIP4K2B, PI4KB | PIK3CD 11/4885PIM1 81/4885GSK3B 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.